These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonists c7E3 Fab on the activated clotting time. Levy JH; Kelley A Circulation; 1997 Nov; 96(10):3793-4. PubMed ID: 9396497 [No Abstract] [Full Text] [Related]
33. The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty. Fischman DL; Savage MP JAMA; 1997 Aug; 278(6):518-9. PubMed ID: 9256229 [No Abstract] [Full Text] [Related]
35. Activating effects of GPIIb/IIIa blockers: an intrinsic consequence of ligand-mimetic properties. Peter K; Schwarz M; Bode C Circulation; 2002 May; 105(21):E180-1. PubMed ID: 12034670 [No Abstract] [Full Text] [Related]
36. Duration of action of GpIIb-IIIa antagonists. Johnson K Crit Care Nurse; 2000 Oct; 20(5):16. PubMed ID: 11878484 [No Abstract] [Full Text] [Related]
37. Use of abciximab for aneurysm coiling. Kapur S; da Silva EJ Anaesthesia; 2006 Jul; 61(7):720-1. PubMed ID: 16792629 [No Abstract] [Full Text] [Related]
38. Abciximab (ReoPro) removal with a hemoconcentrator during cardiopulmonary bypass. Lemmer JH J Thorac Cardiovasc Surg; 1999 Nov; 118(5):980-1. PubMed ID: 10534719 [No Abstract] [Full Text] [Related]